Quality payer — growth is the screen, not the record. Covered by a quality-screened payer base — the index ranks payers on return on equity, return on assets and expected earnings growth. But the payouts have not grown: trailing-12-month distributions are down ~7.9%, the yield is ~1.2%, and the 0.28% fee is the highest of the dividend-growth ETFs here.
Key risk: The growth in the name is a forward-looking screen, not a payout record — distribution totals have been flat to down since 2022, and the monthly amount swung from $0.025 to $0.17 in the past year, so any single month's check misstates the income.
Changes if: Trailing-12-month distributions post sustained growth above the 2022 calendar total of $1.3002 a share, or the fee falls toward the 0.06–0.08% charged by the other dividend-growth ETFs here — either changes the math this verdict rests on.
- ✓Coverage check: The index screens payers on return on equity, return on assets and expected earnings growth, with single names capped at 5% and sectors at 20% at rebalance — the distribution is those payers' dividends passed through across roughly 300 names, not a manufactured payout.
- !Yield check: ~1.2% trailing — $1.1877 a share over the last 12 months on the $98.21 October 23, 2026 close. Low because the screen ranks quality and growth potential, not yield; it is not distress pricing, but it does not carry an income plan by itself.
- ✗Dividend growth check: Trailing-12-month distributions fell ~7.9% — $1.1877 against $1.2890 in the prior 12 months — and sit below the 2022 calendar-year total of $1.3002. Monthly amounts also swing, from $0.025 to $0.17 in the last year, so neither the total nor the monthly check is on a rising line.
What this grade doesn't say: It screens the dividend only — covered, real, compounding. It says nothing about valuation or price: a well-covered payer can still be overpriced, and its price can still fall.